CONCLUSIONS

The advantages of fingolimod over injectable DMTs in terms of patient retention and satisfaction support the use of fingolimod in patients with early RRMS in the real-world setting.

RESULTS

Table 1. Summary of patient demographic and baseline characteristics

Table 2. Proportion of patients (%) satisfied with their medication during the randomized period and the open-label treatment period

Figure 1. PREFER study design

Figure 2. Retention rates in PREFER during the open-label randomized treatment period, tested for significance using four statistical methods

Figure 3. Patient satisfaction in response to the question "Overall, how satisfied are you with your current medication?" assessed at last assessment during the randomized phase and at the entire study period including switches

Figure 4. Primary reasons for switching from randomized treatment during the open-label period. The open-box area at the far-left side (in order of the number of patients) is proportional to the number of patients who switched treatments

References


Disclosures

Heidi Crayton has received consulting fees and/or honoraria from speakers fees and/or honoraria from research support from Acorda, Avanir, Biogen Idec, Genzyme, Novartis, Qiagen, and Teva. Brian Steingo has received consulting fees and/or honoraria from research support from Acorda, Avanir, Biogen Idec, Genzyme, and Teva. DeRen Huang has received honoraria for serving on scientific advisory boards and/or speaker bureaus, and research support from Biogen Idec, Genzyme, Novartis and Teva.

Acknowledgments

Editorial support was provided by Oxford Pharmacology, UK, which was funded by Novartis Pharmaceuticals Corporation.

This study was funded by Novartis Pharmaceuticals Corporation.